171 related articles for article (PubMed ID: 20544810)
1. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study.
Schapira AH; Albrecht S; Barone P; Comella CL; McDermott MP; Mizuno Y; Poewe W; Rascol O; Marek K
Mov Disord; 2010 Aug; 25(11):1627-32. PubMed ID: 20544810
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
[TBL] [Abstract][Full Text] [Related]
3. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
Poewe W; Rascol O; Barone P; Hauser RA; Mizuno Y; Haaksma M; Salin L; Juhel N; Schapira AH;
Neurology; 2011 Aug; 77(8):759-66. PubMed ID: 21832218
[TBL] [Abstract][Full Text] [Related]
4. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
5. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
[TBL] [Abstract][Full Text] [Related]
7. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
[TBL] [Abstract][Full Text] [Related]
8. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.
Rascol O; Barone P; Hauser RA; Mizuno Y; Poewe W; Schapira AH; Salin L; Sohr M; Debieuvre C;
Mov Disord; 2010 Oct; 25(14):2326-32. PubMed ID: 20669265
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
Möller JC; Oertel WH; Köster J; Pezzoli G; Provinciali L
Mov Disord; 2005 May; 20(5):602-10. PubMed ID: 15726540
[TBL] [Abstract][Full Text] [Related]
11. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial.
Kieburtz K;
Mov Disord; 2011 Jan; 26(1):37-44. PubMed ID: 20925067
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.
Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
Mov Disord; 2003 Nov; 18(11):1324-31. PubMed ID: 14639675
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.
Schapira AH; McDermott MP; Barone P; Comella CL; Albrecht S; Hsu HH; Massey DH; Mizuno Y; Poewe W; Rascol O; Marek K
Lancet Neurol; 2013 Aug; 12(8):747-55. PubMed ID: 23726851
[TBL] [Abstract][Full Text] [Related]
14. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
Künig G; Pogarell O; Möller JC; Delf M; Oertel WH
Clin Neuropharmacol; 1999; 22(5):301-5. PubMed ID: 10516884
[TBL] [Abstract][Full Text] [Related]
15. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
Hauser RA; Lew MF; Hurtig HI; Ondo WG; Wojcieszek J; Fitzer-Attas CJ;
Mov Disord; 2009 Mar; 24(4):564-73. PubMed ID: 19086083
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.
Takanashi M; Shimo Y; Hatano T; Oyama G; Hattori N
Drug Res (Stuttg); 2013 Dec; 63(12):639-43. PubMed ID: 23884661
[TBL] [Abstract][Full Text] [Related]
19. The effect of pramipexole on depressive symptoms in Parkinson's disease.
Yasui N; Sekiguchi K; Hamaguchi H; Kanda F
Kobe J Med Sci; 2011 Feb; 56(5):E214-9. PubMed ID: 21937869
[TBL] [Abstract][Full Text] [Related]
20. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
